Rhythm Pharmaceuticals (RYTM)

Executive Summary

Rhythm Pharmaceuticals (NASDAQ: RYTM) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity. Its lead product, IMCIVREE (setmelanotide), is approved in the US for chronic weight management in patients with POMC, PCSK1, or LEPR deficiencies, as well as Bardet-Biedl syndrome. The company has a deep pipeline targeting additional rare obesity disorders, including hypothalamic obesity and Prader-Willi syndrome. Key pipeline assets include setmelanotide in Phase 3 trials for hypothalamic obesity and RM-718, a novel MC4R agonist, in Phase 1/2 for hypothalamic obesity and Prader-Willi syndrome. With a market cap of approximately $6.1 billion, Rhythm is positioned to expand its precision medicine approach to address significant unmet needs in genetic obesity. The company's strategy revolves around identifying and developing targeted therapies for defined patient populations, leveraging its commercial infrastructure and regulatory expertise.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 top-line data for setmelanotide in hypothalamic obesity (NCT05774756)70% success
• Q4 2026Initial Phase 1/2 data for RM-718 in hypothalamic obesity and Prader-Willi syndrome (NCT06239116)50% success
• H2 2027Potential FDA label expansion for setmelanotide to include hypothalamic obesity60% success